Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amnion chorion membrane (ACM) is a bioresorbable biological allograft derived from human placental tissue, specifically comprising the innermost amnion and the adjacent chorion layers. In the field of periodontology, it is utilized as a barrier membrane for guided tissue regeneration (GTR) to treat intrabony defects associated with chronic periodontitis. The membrane functions by providing a physical barrier that prevents the downgrowth of epithelial cells into the periodontal defect, allowing slower-migrating periodontal ligament and bone cells to repopulate the area. Additionally, ACM serves as a reservoir of endogenous growth factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), which promote cell proliferation and tissue healing. Cairo University has evaluated this material in randomized clinical trials, comparing its efficacy to other regenerative materials like demineralized bone matrix (DBM) putty.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amnion chorion membrane.